SoftBank has reportedly considered the possibility of acquiring semiconductor company Marvell Technology, according to sources cited in Bloomberg Deals. The Japanese conglomerate, known for its investments in technology and telecommunications, is understood to have explored a takeover, although no formal offer has been announced. The potential move highlights SoftBank’s ongoing interest in expanding its portfolio within the tech sector, especially in the semiconductor industry.
Meanwhile, in the pharmaceutical sector, Pfizer has been unsuccessful in its legal attempt to block a takeover offer from Novo Nordisk for its diabetes drug Metsera. Pfizer sought to prevent the deal through legal channels, but courts have ruled against the company’s efforts. The outcome is expected to facilitate Novo Nordisk’s acquisition process, bolstering its position in the diabetes treatment market.
These developments underscore ongoing strategic moves by major firms in the technology and healthcare industries. While SoftBank continues to evaluate opportunities within the semiconductor space, Pfizer’s legal setback signals a significant step forward for Novo Nordisk’s expansion plans. The situation remains fluid, with industry observers watching for further updates on both fronts.